Free Trial
The Market Does Not Wait. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion
OTCMKTS:SIGY

Sigyn Therapeutics 11/14/2025 Earnings Report

Sigyn Therapeutics logo
$0.04 +0.01 (+37.15%)
As of 09:49 AM Eastern

Sigyn Therapeutics EPS Results

Actual EPS
-$0.36
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Sigyn Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sigyn Therapeutics Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Sigyn Therapeutics' next earnings date is estimated for Tuesday, May 19, 2026, based on past reporting schedules.

Conference Call Resources

Sigyn Therapeutics Earnings Headlines

Sigyn Therapeutics Delays Annual SEC Filing
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.tc pixel
See More Sigyn Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sigyn Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sigyn Therapeutics and other key companies, straight to your email.

About Sigyn Therapeutics

Sigyn Therapeutics (OTCMKTS:SIGY), a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.

View Sigyn Therapeutics Profile